Imiquimod enhances DNFB mediated contact hypersensitivity in mice

Area of Science:

• Immunology
• Dermatology

Background:

• Imiquimod (Imiq) is a synthetic imidazoquinoline compound known to activate Toll-like receptor 7 (TLR7).
• Toll-like receptors play crucial roles in innate and adaptive immunity, influencing inflammatory responses.

Purpose of the Study:

• To investigate the role of Imiquimod (Imiq) in contact hypersensitivity (CHS).
• To explore the mechanisms involving mast cells in Imiquimod-augmented CHS.

Main Methods:

• Topical application of Imiquimod cream in a dinitrofluorobenzene (DNFB)-induced CHS mouse model.
• Assessment of skin inflammation, dendritic cell (DC) counts in draining lymph nodes (DLNs), and splenic cell proliferation.
• Analysis of mast cell degranulation and histamine release.
• Evaluation of the effects of antihistamines (cromolyn, pyrilamine, cimetidine) on CHS.

Main Results:

• Imiquimod application augmented DNFB-mediated CHS, inducing skin inflammation and increasing DC numbers in DLNs.
• Splenic cell proliferation was higher in mice treated with both DNFB and Imiquimod compared to DNFB alone.
• Imiquimod did not induce mast cell degranulation alone but significantly enhanced it when combined with DNFB, correlating with histamine release.
• Antihistamines significantly attenuated the Imiquimod-induced CHS reaction.

Conclusions:

• Imiquimod augments the intensity of contact hypersensitivity reactions.
• The mechanism involves mast cell degranulation, histamine release, and enhanced dendritic cell homing to draining lymph nodes.
• Blocking histamine action early in allergen contact may be beneficial for alleviating CHS.